Numis Securities reiterated their add rating on shares of Clinigen Group (LON:CLIN) in a research note released on Wednesday. They currently have a GBX 1,208 ($16.38) price objective on the stock.

Several other analysts have also issued reports on the stock. Peel Hunt reiterated a buy rating and issued a GBX 1,350 ($18.31) target price on shares of Clinigen Group in a research note on Wednesday. N+1 Singer reiterated a buy rating and issued a GBX 1,225 ($16.61) target price on shares of Clinigen Group in a research note on Wednesday, November 29th. Royal Bank of Canada reiterated an outperform rating and issued a GBX 1,360 ($18.44) target price on shares of Clinigen Group in a research note on Tuesday, November 7th. Finally, Berenberg Bank began coverage on shares of Clinigen Group in a research note on Wednesday, November 1st. They issued a hold rating and a GBX 1,200 ($16.27) target price for the company. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The stock has an average rating of Buy and an average price target of GBX 1,222.17 ($16.57).

Shares of Clinigen Group (CLIN) opened at GBX 1,059 ($14.36) on Wednesday. Clinigen Group has a one year low of GBX 751.50 ($10.19) and a one year high of GBX 1,187 ($16.10). The company has a market cap of $1,300.00 and a price-to-earnings ratio of 35,300.00.

In other news, insider Chris Rigg sold 4,955 shares of the company’s stock in a transaction on Thursday, November 23rd. The shares were sold at an average price of GBX 1,017 ($13.79), for a total value of £50,392.35 ($68,337.88).

COPYRIGHT VIOLATION WARNING: “Clinigen Group (CLIN) Given Add Rating at Numis Securities” was first published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this report on another domain, it was copied illegally and reposted in violation of US and international copyright laws. The correct version of this report can be accessed at https://theolympiareport.com/2018/01/20/clinigen-group-clin-given-add-rating-at-numis-securities.html.

About Clinigen Group

Clinigen Group plc is a United Kingdom-based pharmaceutical and services company. The Company’s principal activities include management, sale and distribution of pharmaceutical products, which have associated expiry dates. The Company operates through five segments: Clinigen Clinical Trial Services (CTS), which sources commercial medical products for use in clinical studies, including comparator drugs, adjuvant drugs and rescue therapies; Idis Managed Access (MA), which is engaged in the consultancy, development, management and implementation of managed access programs for biotechnology and pharmaceutical companies; Idis Global Access (GA), which offers ethical access to post approval and short-supply medicines; Clinigen Specialty Pharmaceuticals (SP), which manufactures and distributes its own and in-licensed specialist, hospital-only medicines around the world, and Link Healthcare, which distributes pharmaceutical products in South Africa, and the Asia and Pacific region.

Analyst Recommendations for Clinigen Group (LON:CLIN)

Receive News & Ratings for Clinigen Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group and related companies with MarketBeat.com's FREE daily email newsletter.